To evaluate the presence of additional somatic mutational events in other genes critically involved in CRC development, we analyzed BRAF, KRAS, and CTNNB1. All patients were wildtype for BRAF and CTNNB1. Patient P2 showed two heterozygous variants in KRAS (c.35G>A p.(Gly12Asp) and c.38G>A p.(Gly13Asp)) in different adenomatous polyps, while patients P5 and P7, both had a heterozygous KRAS variant in one polyp (P5: c.34G>A p.(Gly12Ser); P7: c.35G>A p.(Gly12Asp)). The gene discussed is KRAS; the disease is colorectal carcinoma.